{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:17:59Z","timestamp":1793830679144,"version":"4.6.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondstiftelsen, St. Olavs hospital"},{"DOI":"10.13039\/100016190","name":"Trond Mohn stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004590","name":"Helse Midt-Norge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004590","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The primary aim was to evaluate whether <jats:italic>anti<\/jats:italic>-3-[<jats:sup>18<\/jats:sup>F]FACBC PET combined with conventional MRI correlated better with histomolecular diagnosis (reference standard) than MRI alone in glioma diagnostics. The ability of <jats:italic>anti<\/jats:italic>-3-[<jats:sup>18<\/jats:sup>F]FACBC to differentiate between molecular and histopathological entities in gliomas was also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective study, patients with suspected primary or recurrent gliomas were recruited from two sites in Norway and examined with PET\/MRI prior to surgery. <jats:italic>Anti<\/jats:italic>-3-[<jats:sup>18<\/jats:sup>F]FACBC uptake (TBR<jats:sub>peak<\/jats:sub>) was compared to histomolecular features in 36 patients. PET results were then added to clinical MRI readings (performed by two neuroradiologists, blinded for histomolecular results and PET data) to assess the predicted tumor characteristics with and without PET.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Histomolecular analyses revealed two CNS WHO grade 1, nine grade 2, eight grade 3, and 17 grade 4 gliomas. All tumors were visible on MRI FLAIR. The sensitivity of contrast-enhanced MRI and <jats:italic>anti<\/jats:italic>-3-[<jats:sup>18<\/jats:sup>F]FACBC PET was 61% (95%CI [45, 77]) and 72% (95%CI [58, 87]), respectively, in the detection of gliomas. Median TBR<jats:sub>peak<\/jats:sub> was 7.1 (range: 1.4\u201319.2) for PET positive tumors. All CNS WHO grade 1 pilocytic astrocytomas\/gangliogliomas, grade 3 oligodendrogliomas, and grade 4 glioblastomas\/astrocytomas were PET positive, while 25% of grade 2\u20133 astrocytomas and 56% of grade 2\u20133 oligodendrogliomas were PET positive. Generally, TBR<jats:sub>peak<\/jats:sub> increased with malignancy grade for diffuse gliomas. A significant difference in PET uptake between CNS WHO grade 2 and 4 gliomas (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and between grade 3 and 4 gliomas (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) was observed. Diffuse IDH wildtype gliomas had significantly higher TBR<jats:sub>peak<\/jats:sub> compared to IDH1\/2 mutated gliomas (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Adding <jats:italic>anti<\/jats:italic>-3-[<jats:sup>18<\/jats:sup>F]FACBC PET to MRI improved the accuracy of predicted glioma grades, types, and IDH status, and yielded 13.9 and 16.7 percentage point improvement in the overall diagnoses for both readers, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>Anti<\/jats:italic>-3-[<jats:sup>18<\/jats:sup>F]FACBC PET demonstrated high uptake in the majority of gliomas, especially in IDH wildtype gliomas, and improved the accuracy of preoperatively predicted glioma diagnoses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration <\/jats:title>\n                <jats:p>ClinicalTrials.gov ID:\u00a0NCT04111588, URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04111588\">https:\/\/clinicaltrials.gov\/study\/NCT04111588<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06437-4","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:02:06Z","timestamp":1696053726000},"page":"496-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnostic accuracy of anti-3-[18F]-FACBC PET\/MRI in gliomas"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-5043","authenticated-orcid":false,"given":"Anna","family":"Karlberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Kjelsberg","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikte Emilie","family":"Vindstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Jarstein","family":"Skjulsvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kon","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Skogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Kvistad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond Velde","family":"Bogsrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Smistad","family":"Myrmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro F.","family":"Giske\u00f8deg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Ingebrigtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Magnus","family":"Berntsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Live","family":"Eikenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"6437_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2022;24:v1\u201395. https:\/\/doi.org\/10.1093\/neuonc\/noac202.","journal-title":"Neuro Oncol"},{"key":"6437_CR2","doi-asserted-by":"publisher","unstructured":"Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494\u2013503; quiz 1 p following 16. https:\/\/doi.org\/10.1038\/ncpneuro0289.","DOI":"10.1038\/ncpneuro0289"},{"key":"6437_CR3","doi-asserted-by":"publisher","first-page":"E973","DOI":"10.9778\/cmajo.20200295","volume":"9","author":"MR Voisin","year":"2021","unstructured":"Voisin MR, Sasikumar S, Mansouri A, Zadeh G. Incidence and prevalence of primary malignant brain tumours in Canada from 1992 to 2017: an epidemiologic study. CMAJ Open. 2021;9:E973\u20139. https:\/\/doi.org\/10.9778\/cmajo.20200295.","journal-title":"CMAJ Open"},{"key":"6437_CR4","doi-asserted-by":"publisher","unstructured":"Lin D, Wang M, Chen Y, Gong J, Chen L, Shi X, et al. Trends in intracranial glioma incidence and mortality in the United States, 1975\u20132018. Front Oncol. 2021;11:748061. https:\/\/doi.org\/10.3389\/fonc.2021.748061.","DOI":"10.3389\/fonc.2021.748061"},{"key":"6437_CR5","unstructured":"\u00c5rsrapport 2022 med resultater og forbedringstiltak fra Kvalitetsregister for hjerne\u2013 og ryggmargssvulster [Annual Report 2022 Brain and spinal cord tumors] Oslo: Cancer Registry of Norway. [Norwegian]. 2023."},{"key":"6437_CR6","unstructured":"WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. Lyon: International Agency for Research on Cancer; 2021."},{"key":"6437_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"6437_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.prro.2022.05.004","volume":"12","author":"LM Halasz","year":"2022","unstructured":"Halasz LM, Attia A, Bradfield L, Brat DJ, Kirkpatrick JP, Laack NN, et al. Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12:370\u201386. https:\/\/doi.org\/10.1016\/j.prro.2022.05.004.","journal-title":"Pract Radiat Oncol"},{"key":"6437_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170\u201386. https:\/\/doi.org\/10.1038\/s41571-020-00447-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"6437_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/neuonc\/nov095","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015;17:1188\u201398. https:\/\/doi.org\/10.1093\/neuonc\/nov095.","journal-title":"Neuro Oncol"},{"key":"6437_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11060-015-1908-9","volume":"125","author":"SJ Fouke","year":"2015","unstructured":"Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ. The role of imaging in the management of adults with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125:457\u201379. https:\/\/doi.org\/10.1007\/s11060-015-1908-9.","journal-title":"J Neurooncol"},{"key":"6437_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1227\/00006123-198902000-00002","volume":"24","author":"PT Chandrasoma","year":"1989","unstructured":"Chandrasoma PT, Smith MM, Apuzzo ML. Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery. 1989;24:160\u20135. https:\/\/doi.org\/10.1227\/00006123-198902000-00002.","journal-title":"Neurosurgery"},{"key":"6437_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF00338192","volume":"14","author":"W Feiden","year":"1991","unstructured":"Feiden W, Steude U, Bise K, Gundisch O. Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings in biopsy cylinders and resected tumor tissue. Neurosurg Rev. 1991;14:51\u20136. https:\/\/doi.org\/10.1007\/BF00338192.","journal-title":"Neurosurg Rev"},{"key":"6437_CR14","doi-asserted-by":"publisher","unstructured":"Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer. 1989;64:442-7. https:\/\/doi.org\/10.1002\/1097-0142(19890715)64:2<442::aid-cncr2820640217>3.0.co;2-s.","DOI":"10.1002\/1097-0142(19890715)64:2<442::aid-cncr2820640217>3.0.co;2-s"},{"key":"6437_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.112.113100","volume":"54","author":"C Huang","year":"2013","unstructured":"Huang C, McConathy J. Radiolabeled amino acids for oncologic imaging. J Nucl Med. 2013;54:1007\u201310. https:\/\/doi.org\/10.2967\/jnumed.112.113100.","journal-title":"J Nucl Med"},{"key":"6437_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fchem.2017.00124","volume":"5","author":"A Sun","year":"2017","unstructured":"Sun A, Liu X, Tang G. Carbon-11 and fluorine-18 labeled amino acid tracers for positron emission tomography imaging of tumors. Front Chem. 2017;5:124. https:\/\/doi.org\/10.3389\/fchem.2017.00124.","journal-title":"Front Chem"},{"key":"6437_CR17","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","volume":"18","author":"NL Albert","year":"2016","unstructured":"Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18:1199\u2013208. https:\/\/doi.org\/10.1093\/neuonc\/now058.","journal-title":"Neuro Oncol"},{"key":"6437_CR18","doi-asserted-by":"publisher","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540\u201357. https:\/\/doi.org\/10.1007\/s00259-018-4207-9.","DOI":"10.1007\/s00259-018-4207-9"},{"key":"6437_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00259-019-04433-1","volume":"47","author":"L Michaud","year":"2020","unstructured":"Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, et al. (18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2020;47:1353\u201367. https:\/\/doi.org\/10.1007\/s00259-019-04433-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6437_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.22038\/aojnmb.2017.8843","volume":"5","author":"N Tsuyuguchi","year":"2017","unstructured":"Tsuyuguchi N, Terakawa Y, Uda T, Nakajo K, Kanemura Y. Diagnosis of brain tumors using amino acid transport PET imaging with (18)F-fluciclovine: a comparative study with L-methyl-(11)C-methionine PET imaging. Asia Ocean J Nucl Med Biol. 2017;5:85\u201394. https:\/\/doi.org\/10.22038\/aojnmb.2017.8843.","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"6437_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00726-014-1863-3","volume":"47","author":"A Habermeier","year":"2015","unstructured":"Habermeier A, Graf J, Sandhofer BF, Boissel JP, Roesch F, Closs EI. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids. 2015;47:335\u201344. https:\/\/doi.org\/10.1007\/s00726-014-1863-3.","journal-title":"Amino Acids"},{"key":"6437_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11307-013-0693-0","volume":"16","author":"S Oka","year":"2014","unstructured":"Oka S, Okudaira H, Ono M, Schuster DM, Goodman MM, Kawai K, et al. Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol. 2014;16:322\u20139. https:\/\/doi.org\/10.1007\/s11307-013-0693-0.","journal-title":"Mol Imaging Biol"},{"key":"6437_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/RLU.0000000000002641","volume":"44","author":"TV Bogsrud","year":"2019","unstructured":"Bogsrud TV, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P, et al. 18F-Fluciclovine PET\/CT in suspected residual or recurrent high-grade glioma. Clin Nucl Med. 2019;44:605\u201311. https:\/\/doi.org\/10.1097\/RLU.0000000000002641.","journal-title":"Clin Nucl Med"},{"key":"6437_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/RLU.0000000000002610","volume":"44","author":"A Karlberg","year":"2019","unstructured":"Karlberg A, Berntsen EM, Johansen H, Skjulsvik AJ, Reinertsen I, Dai HY, et al. 18F-FACBC PET\/MRI in diagnostic assessment and neurosurgery of gliomas. Clin Nucl Med. 2019;44:550\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000002610.","journal-title":"Clin Nucl Med"},{"key":"6437_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s12149-016-1102-y","volume":"30","author":"A Kondo","year":"2016","unstructured":"Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K, et al. Phase IIa clinical study of [(18)F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med. 2016;30:608\u201318. https:\/\/doi.org\/10.1007\/s12149-016-1102-y.","journal-title":"Ann Nucl Med"},{"key":"6437_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.22038\/aojnmb.2016.7869","volume":"5","author":"T Wakabayashi","year":"2017","unstructured":"Wakabayashi T, Iuchi T, Tsuyuguchi N, Nishikawa R, Arakawa Y, Sasayama T, et al. Diagnostic performance and safety of positron emission tomography using (18)F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial. Asia Ocean J Nucl Med Biol. 2017;5:10\u201321. https:\/\/doi.org\/10.22038\/aojnmb.2016.7869.","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"6437_CR27","doi-asserted-by":"publisher","unstructured":"Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, et al. [F-18]Fluciclovine PET discrimination between high- and low-grade gliomas. Ejnmmi Res. 2018;8. ARTN 67. https:\/\/doi.org\/10.1186\/s13550-018-0415-3.","DOI":"10.1186\/s13550-018-0415-3"},{"key":"6437_CR28","first-page":"331","volume":"40","author":"TM Shoup","year":"1999","unstructured":"Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331\u20138.","journal-title":"J Nucl Med."},{"key":"6437_CR29","doi-asserted-by":"publisher","unstructured":"Laudicella R, Albano D, Alongi P, Argiroffi G, Bauckneht M, Baldari S, et al. (18)F-Facbc in prostate cancer: a systematic review and meta-analysis. Cancers (Basel). 2019;11:1348. https:\/\/doi.org\/10.3390\/cancers11091348.","DOI":"10.3390\/cancers11091348"},{"key":"6437_CR30","doi-asserted-by":"publisher","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. https:\/\/doi.org\/10.1136\/bmj.h5527.","DOI":"10.1136\/bmj.h5527"},{"key":"6437_CR31","doi-asserted-by":"publisher","unstructured":"Ladefoged CN, Hansen AE, Henriksen OM, Bruun FJ, Eikenes L, Oen SK, et al. AI-driven attenuation correction for brain PET\/MRI: clinical evaluation of a dementia cohort and importance of the training group size. Neuroimage. 2020;222:117221. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.117221.","DOI":"10.1016\/j.neuroimage.2020.117221"},{"key":"6437_CR32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fnins.2018.01005","volume":"12","author":"CN Ladefoged","year":"2018","unstructured":"Ladefoged CN, Marner L, Hindsholm A, Law I, Hojgaard L, Andersen FL. Deep learning based attenuation correction of PET\/MRI in pediatric brain tumor patients: evaluation in a clinical setting. Front Neurosci. 2018;12:1005. https:\/\/doi.org\/10.3389\/fnins.2018.01005.","journal-title":"Front Neurosci."},{"key":"6437_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1148\/radiol.213063","volume":"304","author":"DR Johnson","year":"2022","unstructured":"Johnson DR, Giannini C, Vaubel RA, Morris JM, Eckel LJ, Kaufmann TJ, et al. A radiologist\u2019s guide to the 2021 WHO Central Nervous System Tumor Classification: part I\u2014key concepts and the spectrum of diffuse gliomas. Radiology. 2022;304:494\u2013508. https:\/\/doi.org\/10.1148\/radiol.213063.","journal-title":"Radiology."},{"key":"6437_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00234-022-03015-7","volume":"65","author":"AN Kamble","year":"2023","unstructured":"Kamble AN, Agrawal NK, Koundal S, Bhargava S, Kamble AN, Joyner DA, et al. Imaging-based stratification of adult gliomas prognosticates survival and correlates with the 2021 WHO classification. Neuroradiology. 2023;65:41\u201354. https:\/\/doi.org\/10.1007\/s00234-022-03015-7.","journal-title":"Neuroradiology."},{"key":"6437_CR35","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00234-022-03008-6","volume":"64","author":"C McNamara","year":"2022","unstructured":"McNamara C, Mankad K, Thust S, Dixon L, Limback-Stanic C, D\u2019Arco F, et al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology. 2022;64:1919\u201350. https:\/\/doi.org\/10.1007\/s00234-022-03008-6.","journal-title":"Neuroradiology."},{"key":"6437_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13550-017-0295-y","volume":"7","author":"M Unterrainer","year":"2017","unstructured":"Unterrainer M, Vettermann F, Brendel M, Holzgreve A, Lifschitz M, Zahringer M, et al. Towards standardization of (18)F-FET PET imaging: do we need a consistent method of background activity assessment? EJNMMI Res. 2017;7:48. https:\/\/doi.org\/10.1186\/s13550-017-0295-y.","journal-title":"EJNMMI Res."},{"key":"6437_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276\u201382.","journal-title":"Biochem Med (Zagreb)."},{"key":"6437_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med."},{"key":"6437_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387","volume-title":"Applied logistic regression","author":"JRDW Hosmer","year":"2013","unstructured":"Hosmer JRDW, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken, New Jersey: Wiley & Sons, Inc.; 2013.","edition":"3"},{"issue":"989","key":"6437_CR40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.wneu.2017.08.085","volume":"108","author":"A Karlberg","year":"2017","unstructured":"Karlberg A, Berntsen EM, Johansen H, Myrthue M, Skjulsvik AJ, Reinertsen I, et al. Multimodal (18)F-fluciclovine PET\/MRI and ultrasound-guided neurosurgery of an anaplastic oligodendroglioma. World Neurosurg. 2017;108(989):e1\u20138. https:\/\/doi.org\/10.1016\/j.wneu.2017.08.085.","journal-title":"World Neurosurg."},{"key":"6437_CR41","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3171\/2022.1.JNS212514","volume":"137","author":"AS Jakola","year":"2022","unstructured":"Jakola AS, Pedersen LK, Skjulsvik AJ, Myrmel K, Sjavik K, Solheim O. The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study. J Neurosurg. 2022;137:1321\u20138. https:\/\/doi.org\/10.3171\/2022.1.JNS212514.","journal-title":"J Neurosurg."},{"key":"6437_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1227\/NEU.0000000000001753","volume":"90","author":"AA Aabedi","year":"2022","unstructured":"Aabedi AA, Young JS, Zhang Y, Ammanuel S, Morshed RA, Dalle Ore C, et al. Association of neurological impairment on the relative benefit of maximal extent of resection in chemoradiation-treated newly diagnosed isocitrate dehydrogenase wild-type glioblastoma. Neurosurgery. 2022;90:124\u201330. https:\/\/doi.org\/10.1227\/NEU.0000000000001753.","journal-title":"Neurosurgery"},{"key":"6437_CR43","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3171\/2019.6.JNS19972","volume":"133","author":"VK Kavouridis","year":"2019","unstructured":"Kavouridis VK, Boaro A, Dorr J, Cho EY, Iorgulescu JB, Reardon DA, et al. Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg. 2019;133:1291\u2013301. https:\/\/doi.org\/10.3171\/2019.6.JNS19972.","journal-title":"J Neurosurg."},{"key":"6437_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.ijrobp.2010.07.002","volume":"81","author":"AL Grosu","year":"2011","unstructured":"Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.07.002.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6437_CR45","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2967\/jnumed.114.140608","volume":"55","author":"C Lapa","year":"2014","unstructured":"Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, et al. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014;55:1611\u20136. https:\/\/doi.org\/10.2967\/jnumed.114.140608.","journal-title":"J Nucl Med"},{"key":"6437_CR46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","volume":"40","author":"AW Glaudemans","year":"2013","unstructured":"Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615\u201335. https:\/\/doi.org\/10.1007\/s00259-012-2295-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6437_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/neuonc\/nos300","volume":"15","author":"M Hutterer","year":"2013","unstructured":"Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013;15:341\u201351. https:\/\/doi.org\/10.1093\/neuonc\/nos300.","journal-title":"Neuro Oncol."},{"key":"6437_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejrad.2008.04.018","volume":"71","author":"CJ Ledezma","year":"2009","unstructured":"Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-FDOPA PET\/MRI fusion in patients with primary\/recurrent gliomas: initial experience. Eur J Radiol. 2009;71:242\u20138. https:\/\/doi.org\/10.1016\/j.ejrad.2008.04.018.","journal-title":"Eur J Radiol."},{"key":"6437_CR49","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/neuonc\/not002","volume":"15","author":"DH Pafundi","year":"2013","unstructured":"Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15:1058\u201367. https:\/\/doi.org\/10.1093\/neuonc\/not002.","journal-title":"Neuro Oncol."},{"key":"6437_CR50","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/RLU.0b013e3181becfe0","volume":"34","author":"M Tripathi","year":"2009","unstructured":"Tripathi M, Sharma R, D\u2019Souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET\/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878\u201383. https:\/\/doi.org\/10.1097\/RLU.0b013e3181becfe0.","journal-title":"Clin Nucl Med."},{"key":"6437_CR51","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00259-012-2109-9","volume":"39","author":"NL Jansen","year":"2012","unstructured":"Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012;39:1021\u20139. https:\/\/doi.org\/10.1007\/s00259-012-2109-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6437_CR52","doi-asserted-by":"publisher","unstructured":"Werner JM, Lohmann P, Fink GR, Langen KJ, Galldiks N. Current landscape and emerging fields of PET imaging in patients with brain tumors. Molecules. 2020;25:1471. https:\/\/doi.org\/10.3390\/molecules25061471.","DOI":"10.3390\/molecules25061471"},{"key":"6437_CR53","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/wnl.50.5.1316","volume":"50","author":"K Herholz","year":"1998","unstructured":"Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316\u201322. https:\/\/doi.org\/10.1212\/wnl.50.5.1316.","journal-title":"Neurology."},{"key":"6437_CR54","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/neuonc\/noac040","volume":"24","author":"G Ninatti","year":"2022","unstructured":"Ninatti G, Sollini M, Bono B, Gozzi N, Fedorov D, Antunovic L, et al. Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas. Neuro Oncol. 2022;24:1546\u201356. https:\/\/doi.org\/10.1093\/neuonc\/noac040.","journal-title":"Neuro Oncol."},{"key":"6437_CR55","doi-asserted-by":"publisher","unstructured":"Sharma N, Mallela AN, Shi DD, Tang LW, Abou-Al-Shaar H, Gersey ZC, et al. Isocitrate dehydrogenase mutations in gliomas: a review of current understanding and trials. Neurooncol Adv. 2023;5:vdad053. https:\/\/doi.org\/10.1093\/noajnl\/vdad053.","DOI":"10.1093\/noajnl\/vdad053"},{"key":"6437_CR56","doi-asserted-by":"publisher","first-page":"153601211989408","DOI":"10.1177\/1536012119894087","volume":"18","author":"N Kudulaiti","year":"2019","unstructured":"Kudulaiti N, Zhang H, Qiu T, Lu J, Aibaidula A, Zhang Z, et al. The relationship between IDH1 mutation status and metabolic imaging in nonenhancing supratentorial diffuse gliomas: a (11)C-MET PET study. Mol Imaging. 2019;18:1536012119894087. https:\/\/doi.org\/10.1177\/1536012119894087.","journal-title":"Mol Imaging."},{"key":"6437_CR57","doi-asserted-by":"publisher","first-page":"13328","DOI":"10.1038\/s41598-018-31806-7","volume":"8","author":"P Lohmann","year":"2018","unstructured":"Lohmann P, Lerche C, Bauer EK, Steger J, Stoffels G, Blau T, et al. Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep. 2018;8:13328. https:\/\/doi.org\/10.1038\/s41598-018-31806-7.","journal-title":"Sci Rep."},{"key":"6437_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2967\/jnumed.120.261545","volume":"63","author":"T Zaragori","year":"2022","unstructured":"Zaragori T, Oster J, Roch V, Hossu G, Chawki MB, Grignon R, et al. (18)F-FDOPA PET for the noninvasive prediction of glioma molecular parameters: a radiomics study. J Nucl Med. 2022;63:147\u201357. https:\/\/doi.org\/10.2967\/jnumed.120.261545.","journal-title":"J Nucl Med."},{"key":"6437_CR59","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/cyt.12405","volume":"28","author":"T Gi","year":"2017","unstructured":"Gi T, Sato Y, Tokumitsu T, Yamashita A, Moriguchi-Goto S, Takeshima H, et al. Microvascular proliferation of brain metastases mimics glioblastomas in squash cytology. Cytopathology. 2017;28:228\u201334. https:\/\/doi.org\/10.1111\/cyt.12405.","journal-title":"Cytopathology."},{"key":"6437_CR60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/neuonc\/nor054","volume":"13","author":"C la Fougere","year":"2011","unstructured":"la Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011;13:806\u201319. https:\/\/doi.org\/10.1093\/neuonc\/nor054.","journal-title":"Neuro Oncol."},{"key":"6437_CR61","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00259-019-04509-y","volume":"47","author":"M Ginet","year":"2020","unstructured":"Ginet M, Zaragori T, Marie PY, Roch V, Gauchotte G, Rech F, et al. Integration of dynamic parameters in the analysis of (18)F-FDopa PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging. 2020;47:1381\u201390. https:\/\/doi.org\/10.1007\/s00259-019-04509-y.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6437_CR62","doi-asserted-by":"publisher","unstructured":"Zaragori T, Doyen M, Rech F, Blonski M, Taillandier L, Imbert L, et al. Dynamic (18)F-FDopa PET imaging for newly diagnosed gliomas: is a semiquantitative model sufficient? Front Oncol. 2021;11:735257. https:\/\/doi.org\/10.3389\/fonc.2021.735257.","DOI":"10.3389\/fonc.2021.735257"},{"key":"6437_CR63","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1055\/s-0039-1693732","volume":"58","author":"G Cilluffo","year":"2019","unstructured":"Cilluffo G, Fasola S, Ferrante G, Montalbano L, Baiardini I, Indinnimeo L, et al. Overrating classifier performance in ROC analysis in the absence of a test set: evidence from simulation and Italian CARATkids validation. Methods Inf Med. 2019;58:e27\u201342. https:\/\/doi.org\/10.1055\/s-0039-1693732.","journal-title":"Methods Inf Med."},{"key":"6437_CR64","doi-asserted-by":"publisher","unstructured":"Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139:603-8. https:\/\/doi.org\/10.1007\/s00401-020-02127-9.","DOI":"10.1007\/s00401-020-02127-9"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:03:34Z","timestamp":1704704614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6437"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06437-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol is available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study protocol"}},{"value":"The study was approved by the Regional Ethics Committee (REC Central Norway, reference numbers 2016\/279 and 2018\/2243).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}